Astrazeneca Pharma India Ltd vs Bajaj Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8530 as of 18 May 16:01 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of Bajaj Healthcare Ltd changed from 7.8 on March 2021 to 53.7 on March 2025 . This represents a CAGR of 47.09% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of Bajaj Healthcare Ltd changed from ₹ 650.77 crore on March 2021 to ₹ 2121 crore on March 2025 . This represents a CAGR of 26.66% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 618.18 crore. This represent the decline of -100% The revenue of Bajaj Healthcare Ltd for the Mar '26 is ₹ 156.01 crore as compare to the Dec '25 revenue of ₹ 162.87 crore. This represent the decline of -4.21% The ebitda of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 51.44 crore. This represent the decline of -100% The ebitda of Bajaj Healthcare Ltd for the Mar '26 is ₹ -11.05 crore as compare to the Dec '25 ebitda of ₹ 31.9 crore. This represent the decline of -134% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Bajaj Healthcare Ltd changed from ₹ 7.13 crore to ₹ -22.85 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Bajaj Healthcare Ltd changed from 4.57 % on March 2021 to 7.99 % on March 2025 . This represents a CAGR of 11.82% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Bajaj Healthcare Ltd

Incorporated in 1993, Maharashtra-based Bajaj Healthcare Limited is one of India's large scale and vertically integrated pharmaceutical manufacturer for quality-conscious customers.
The Company is engaged in the manufacturing and exporting of Active Pharmaceutical Ingredient (APIs), Intermediates, Finished Dosage Forms & Nutraceuticals. Company commenced its operations in 1993 with a single unit at Tarapur.
It became a public company in 2005 and listed its shares in the Indian stock exchanges in 2016. With Headquartered in Thane, Company has established 3 API plants in Gujarat and Maharashtra.
It has 4 units for APIs/ intermediates and one unit for formulation, which are designed to meet the requirements of both advanced as well as emerging market opportunities.
In 2008, the Company acquired Formulations plant at Manjusar, Vadodara and have converted it into WHO-GMP compliant facility.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Bajaj Healthcare Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Bajaj Healthcare Ltd?

Market cap of Astrazeneca Pharma India Ltd is 21,221 Cr while Market cap of Bajaj Healthcare Ltd is 959 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Bajaj Healthcare Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Bajaj Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Bajaj Healthcare Ltd?

As of May 18, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8488.45. On the other hand, Bajaj Healthcare Ltd stock price is INR ₹284.95.

How do dividend payouts of Astrazeneca Pharma India Ltd and Bajaj Healthcare Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Bajaj Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.